Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Table 4
EBV viremia in EBV sero(+) versus sero(−) patients in the DES and non-DES groups.
DES group ()
Non-DES group ()
value (DES versus non-DES)
EBV sero(+) ()
EBV sero(−) ()
value (sero+ versus −)
EBV sero(+) ()
EBV sero(−) ()
value (sero+ versus −)
In EBV sero(+)
In EBV sero(−)
EBV-PCR > 5.0 copies/PCR
Viremia rate
14.4 ± 4.1
16.7 ± 10.8
0.29
32.0 ± 5.3
36.7 ± 9.0
0.02
<0.001
0.22
1st viremia (m post-Tx)
19.8 ± 20.0
7.1 ± 0.9
0.01
14.6 ± 20.8
5.5 ± 5.9
0.00
0.29
0.45
Peak levels (copies/PCR)
183 ± 531
29 ± 17
0.18
62 ± 130
160 ± 189
0.14
0.29
0.06
Duration (m)
7.0 ± 18.1
3.3 ± 2.8
0.45
4.1 ± 6.2
7.1 ± 6.6
0.21
0.46
0.37
EBV-PCR > 30 copies/PCR
Viremia rate
2.8 ± 1.1
8.3 ± 8.0
0.20
11.1 ± 3.3
26.5 ± 8.2
<0.001
<0.01
0.21
1st viremia (m post-Tx)
15.6 ± 21.2
6.2 ± 0.0
na
11.1 ± 17.3
4.7 ± 6.3
0.12
0.62
na
Peak levels (copies/PCR)
527 ± 817
46 ± 0.0
na
141 ± 185
214 ± 197
0.40
0.25
na
Duration (m)
18.5 ± 27.9
6.0 ± 0.0
na
7.3 ± 7.9
8.0 ± 6.9
0.83
0.33
na
EBV-PCR > 50 copies/PCR
Viremia rate
2.5 ± 1.1
0
0.61
5.4 ± 1.7
23.3 ± 7.9
<0.001
0.09
0.08
1st viremia (m post-Tx)
9.4 ± 7.8
na
na
7.1 ± 9.2
5.2 ± 6.6
0.59
0.60
na
Peak levels (copies/PCR)
691 ± 884
na
na
213 ± 214
239 ± 197
0.79
0.28
na
Duration (m)
23.6 ± 30.6
na
na
8.1 ± 8.5
8.6 ± 7.2
0.89
0.31
na
PTLD, (%)
0 (0)
0 (0)
na
0 (0)
0 (0)
na
na
na
The viremia rates (% ± standard error [SE]) at 5 years after transplant (Tx) were estimated by the Kaplan-Meier method and the group differences were assessed by the log-rank test. Results for 1st viremia, peak levels, and duration are mean ± standard deviation (SD). DES: desensitization, PTLD: posttransplant lymphoproliferative disorder, and post-Tx: posttransplant.
